Details of Disease

General Information of Disease (ID: DISDDD65)

• Disease Name: Hypopharyngeal squamous cell carcinoma
• Synonyms: squamous cell carcinoma of the hypopharynx; hypopharyngeal epidermoid carcinoma; epidermoid carcinoma of hypopharynx; hypopharyngeal throat squamous cell cancer; squamous cell carcinoma of hypopharynx; hypopharyngeal squamous cell carcinoma; epidermoid carcinoma of the hypopharynx
• Disease Class: 2B6D: Hypopharyngeal cancer
• Definition: A squamous cell carcinoma that involves the hypopharynx.
• Disease Hierarchy:
  DISQVIFL: Squamous cell carcinoma
  DISLOSB4: Hypopharyngeal carcinoma
  DISWZMVP: Pharyngeal squamous cell carcinoma
  DISDDD65: Hypopharyngeal squamous cell carcinoma
• ICD Code: ICD-11: ICD-11: 2B6D.0
• Disease Identifiers:
  MONDO ID: MONDO_0044638
  MESH ID: D000077195
  UMLS CUI: C0280321
  MedGen ID: 79102
  Orphanet ID: 494547

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TNFRSF10B	TTW20TU	Limited	SusceptibilityMutation	[2]
ADAM10	TTVXEGU	Strong	Altered Expression	[3]
HAX1	TT21BYA	Strong	Altered Expression	[4]
PDPK1	TTYMGWX	Strong	Altered Expression	[5]
STK33	TTP34DQ	Strong	Biomarker	[6]

This Disease Is Related to 12 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ING1	OTEZBRKW	Limited	SomaticCausalMutation	[7]
BTF3	OT5ZZFJL	Strong	Altered Expression	[8]
CARTPT	OTTE4V9S	Strong	Biomarker	[9]
CENPH	OTPOO9LK	Strong	Altered Expression	[10]
DCBLD2	OTB71I02	Strong	Altered Expression	[11]
GRK6	OT4LZTP9	Strong	Biomarker	[12]
PAFAH1B3	OT6A9JT8	Strong	Altered Expression	[13]
PCDH20	OTFSNRXK	Strong	Altered Expression	[14]
PEG10	OTWD2278	Strong	Altered Expression	[15]
PHLPP1	OTIFXW8D	Strong	Altered Expression	[16]
PHLPP2	OTXB1OUI	Strong	Altered Expression	[16]
TCN1	OTW6A49Y	Strong	Biomarker	[17]

References

• [1] ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
• [2] Causes of death in a cohort of 260 plutonium workers.Health Phys. 1998 Sep;75(3):236-40. doi: 10.1097/00004032-199809000-00001.
• [3] Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.Oncol Rep. 2017 Aug;38(2):866-874. doi: 10.3892/or.2017.5761. Epub 2017 Jun 27.
• [4] Abnormal expression of HAX? is associated with cellular proliferation and migration in human hypopharyngeal squamous cell carcinoma.Mol Med Rep. 2017 Oct;16(4):4664-4670. doi: 10.3892/mmr.2017.7155. Epub 2017 Aug 3.
• [5] PDK1 promotes metastasis by inducing epithelial-mesenchymal transition in hypopharyngeal carcinoma via the Notch1 signaling pathway.Exp Cell Res. 2020 Jan 15;386(2):111746. doi: 10.1016/j.yexcr.2019.111746. Epub 2019 Nov 25.
• [6] STK33 potentiates the malignancy of hypopharyngeal squamous carcinoma: Possible relation to calcium.Cancer Biol Ther. 2016 Sep;17(9):976-84. doi: 10.1080/15384047.2016.1210739. Epub 2016 Jul 14.
• [7] Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res. 2000 Jun 15;60(12):3143-6.
• [8] Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma.Biomed Pharmacother. 2019 Oct;118:109211. doi: 10.1016/j.biopha.2019.109211. Epub 2019 Aug 9.
• [9] The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma.Onco Targets Ther. 2018 Oct 16;11:7053-7059. doi: 10.2147/OTT.S175516. eCollection 2018.
• [10] Role of centromere protein H and Ki67 in relapse-free survival of patients after primary surgery for hypopharyngeal cancer.Asian Pac J Cancer Prev. 2012;13(3):821-5. doi: 10.7314/apjcp.2012.13.3.821.
• [11] Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature.Br J Cancer. 2014 Jul 15;111(2):386-94. doi: 10.1038/bjc.2014.293. Epub 2014 Jun 10.
• [12] Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma.Oncol Rep. 2016 Feb;35(2):1027-33. doi: 10.3892/or.2015.4469. Epub 2015 Dec 1.
• [13] Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.Onco Targets Ther. 2019 Apr 11;12:2799-2808. doi: 10.2147/OTT.S196324. eCollection 2019.
• [14] PCDH20acts as a tumour-suppressor gene through the Wnt/-catenin signalling pathway in hypopharyngeal squamous cell carcinoma.Cancer Biomark. 2019;26(2):209-217. doi: 10.3233/CBM-190442.
• [15] Overexpression of long noncoding RNA PEG10 promotes proliferation, invasion and metastasis of hypopharyngeal squamous cell carcinoma.Oncol Lett. 2017 Sep;14(3):2919-2925. doi: 10.3892/ol.2017.6498. Epub 2017 Jun 30.
• [16] Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma.PLoS One. 2015 Mar 20;10(3):e0119405. doi: 10.1371/journal.pone.0119405. eCollection 2015.
• [17] Transcobalamin I: a novel prognostic biomarker of neoadjuvant chemotherapy in locally advanced hypopharyngeal squamous cell cancers.Onco Targets Ther. 2018 Jul 24;11:4253-4261. doi: 10.2147/OTT.S166514. eCollection 2018.